JPRN-UMIN000007173RecruitingPhase 2

Randomized phase II study of gemcitabine and S-1 combination therapy versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer - Randomized phase II study of gemcitabine and S-1 combination therapy versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer

Tokai University Hospital Kanagawa Cancer Center0 sites90 target enrollmentStarted: February 1, 2012Last updated: October 17, 2023

Conditions

Trial Snapshot

No summary available.

•1)With moderate or more pleural effusion/ ascites 2)Interstitial pneumonia or fibroid lung 3)Cardiac insufficiency or myocardial infarction within six months 4)Active bacterial or fungous infection 5)Uncontrollable diabetes mellitus 6)Psychosis or severe mental disorder 7)Severe drug allergy 8)Simultaneous or metachronous (within 3 years) double cancers, with the exception of intramucosal tumor curable with local therapy 9) Previous chemotherapy or radiotherapy against any other malignancies within 3 years 10)Over 6 months after adjuvant gemcitabine chemotherapy 11)With CNS metastas 12)Patients requiring the administration of flucytosine, phenytoin or warfarin potassium 13)Pregnant, lactating women or women of childbearing potential 14)Men who want to get partner pregnant 15)Inadequate physical condition, as diagnosed by primary physician

Sponsor

Tokai University Hospital Kanagawa Cancer Center